GO:0051725 protein de-ADP-ribosylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051725 protein de-ADP-ribosylation is the biological process that removes one or more ADP-ribose residues from a protein, reversing ADP-ribosylation.
• This process is catalyzed by ADP-ribosylhydrolases, including macrodomain-containing proteins, Nudix hydrolases, and NADARs, which hydrolyze the ADP-ribose-protein bond.
• De-ADP-ribosylation regulates key cellular proteins such as 53BP1, actin, and Rho, influencing DNA repair, cytoskeletal dynamics, and signal transduction.
• Bacterial toxins like Clostridium botulinum C3 and C2 toxins, as well as iota-toxin, can both ADP-ribosylate and de-ADP-ribosylate host proteins, highlighting the reversible nature of this modification.
• Dysregulation of de-ADP-ribosylation is linked to cancer, neurodegeneration, and infectious diseases, making it a target for therapeutic intervention.
• Studying protein de-ADP-ribosylation requires specialized assays, including mono-ADP-ribosylhydrolase assays and CRISPR-based models to dissect gene function.
Description
Protein de-ADP-ribosylation (GO:0051725) is the enzymatic removal of ADP-ribose moieties from target proteins, a reversible post-translational modification that counters ADP-ribosylation. This process is essential for maintaining cellular homeostasis, as it regulates the duration and amplitude of ADP-ribose signaling in diverse pathways, including DNA damage repair, immune responses, and cytoskeletal organization. Researchers study de-ADP-ribosylation to understand how cells dynamically control protein function and to identify therapeutic targets for diseases such as cancer and neurodegeneration. The reaction is catalyzed by a family of enzymes known as ADP-ribosylhydrolases, which include macrodomain proteins, Nudix hydrolases, and NADARs, each with distinct substrate specificities and regulatory mechanisms. Given its broad impact on cell biology, protein de-ADP-ribosylation is a focal point for drug discovery and functional genomics.
protein de-ADP-ribosylation At A Glance
| GO ID | GO:0051725 |
|---|---|
| GO term | protein de-ADP-ribosylation |
| Ontology | biological_process |
| Synonym | poly(ADP-ribose) removal from protein; protein amino acid de-ADP-ribosylation; protein poly(ADP-ribose) catabolic process; protein poly(ADP-ribose) catabolism; protein poly(ADP-ribose) degradation; protein poly(ADP-ribose) hydrolysis; removal of ADP-ribose from protein |
| Major function | Reverses ADP-ribosylation, regulating protein activity, stability, and interactions. |
| Catalytic enzymes | ADP-ribosylhydrolases, including macrodomain proteins, Nudix hydrolases, and NADARs. |
| Substrates | Proteins modified by mono- or poly-ADP-ribosylation, such as 53BP1, actin, and Rho. |
| Biological impact | Controls DNA repair, cytoskeletal dynamics, and signal transduction. |
What Is GO:0051725?
Protein de-ADP-ribosylation is the biological process that removes one or more ADP-ribose residues from a protein, effectively reversing the covalent attachment of ADP-ribose. This process can target mono-ADP-ribosylated or poly-ADP-ribosylated proteins and is mediated by specific hydrolases that cleave the ADP-ribose-protein bond.
Why Is protein de-ADP-ribosylation Important in Cell Biology?
Protein de-ADP-ribosylation is critical for cellular physiology because it counteracts ADP-ribosylation, a modification that regulates protein function in response to DNA damage, infection, and stress. By removing ADP-ribose, hydrolases such as NUDT16 and macrodomain proteins ensure proper DNA repair and prevent genomic instability. Dysregulation of this process contributes to cancer, neurodegeneration, and infectious diseases, making it a promising target for therapeutic development.
• Maintains protein homeostasis by reversing ADP-ribosylation.
• Regulates DNA damage response and repair, particularly via 53BP1.
• Modulates cytoskeletal dynamics through actin and Rho de-ADP-ribosylation.
• Influences immune cell function, as shown in human neutrophils.
• Plays a role in bacterial pathogenesis by counteracting toxin-mediated ADP-ribosylation.
• Contributes to cancer progression when dysregulated, affecting 53BP1 stability.
• Involved in neurodegeneration through impaired DNA repair.
• Provides targets for antiviral and antibacterial therapies.
• Essential for understanding reversible post-translational modifications.
• Enables development of CRISPR models to study gene function.
What Happens During protein de-ADP-ribosylation?
Recognition of ADP-ribosylated substrates
In simple terms: The enzyme finds the protein that has ADP-ribose attached to it.
De-ADP-ribosylation begins with the recognition of target proteins carrying mono- or poly-ADP-ribose modifications. Hydrolases such as macrodomain proteins and Nudix hydrolases bind to ADP-ribose moieties with high specificity, often through conserved domains that interact with the ADP-ribose unit. For example, NUDT16 recognizes ADP-ribosylated 53BP1 and reverses the modification to regulate its function.
Hydrolysis of the ADP-ribose-protein bond
In simple terms: The enzyme cuts the bond between ADP-ribose and the protein.
Once bound, the hydrolase catalyzes the hydrolysis of the bond linking ADP-ribose to the target protein. This reaction can remove a single ADP-ribose unit (mono-ADP-ribosylation) or multiple units (poly-ADP-ribosylation), depending on the enzyme and substrate. NADARs specifically reverse DNA ADP-ribosylation, demonstrating substrate specificity. The hydrolysis is often regulated by cofactors such as EDTA, guanine nucleotides, and pH, as shown for Rho de-ADP-ribosylation by Clostridium botulinum C3.
Release of ADP-ribose and restoration of protein function
In simple terms: The ADP-ribose is released, and the protein goes back to its original state.
After cleavage, the ADP-ribose moiety is released, and the target protein is restored to its unmodified form. This reversal can reactivate or alter protein function, as seen with actin de-ADP-ribosylation by Clostridium perfringens iota-toxin and C2 toxin. In human neutrophils, de-ADP-ribosylation of endogenous acceptor proteins is regulated by DNA, indicating a dynamic interplay between modification and removal.
Regulation and specificity of de-ADP-ribosylation
In simple terms: The process is controlled so that only the right proteins are modified at the right time.
De-ADP-ribosylation is tightly regulated to ensure specificity. Enzymes like NUDT16 exhibit substrate preference for specific proteins such as 53BP1, while NADARs target DNA-linked ADP-ribose. The activity of these hydrolases can be modulated by cellular signals, including DNA damage and immune activation. This regulation prevents unintended removal of ADP-ribose and maintains signaling fidelity.
Key Genes Involved in GO:0051725 protein de-ADP-ribosylation
The following genes and proteins are key players in protein de-ADP-ribosylation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NUDT16 | Nudix hydrolase that reverses 53BP1 ADP-ribosylation | Regulates DNA repair and genome stability; potential cancer target |
| MACROD1 | Macrodomain-containing hydrolase that removes mono-ADP-ribose | Implicated in transcriptional regulation and DNA repair |
| MACROD2 | Macrodomain hydrolase with specificity for mono-ADP-ribosylated proteins | Linked to neurodevelopmental disorders and cancer |
| TARG1 | Terminal ADP-ribose glycohydrolase that removes ADP-ribose from proteins | Mutations cause neurodegeneration; involved in DNA damage response |
| ARH1 | ADP-ribosylhydrolase that acts on mono-ADP-ribosylated proteins | Regulates cell signaling and stress responses |
| ARH2 | ADP-ribosylhydrolase with roles in protein de-ADP-ribosylation | Potential tumor suppressor |
| ARH3 | ADP-ribosylhydrolase that removes poly-ADP-ribose | Critical for DNA repair and cell survival |
| PARG | Poly(ADP-ribose) glycohydrolase that degrades poly-ADP-ribose chains | Key regulator of DNA damage response and apoptosis |
| NADAR | Reverses DNA ADP-ribosylation | Bacterial defense and genome maintenance |
| Rho | Small GTPase de-ADP-ribosylated by C3 toxin | Regulates cytoskeleton and cell motility |
| Actin | Cytoskeletal protein de-ADP-ribosylated by iota-toxin and C2 toxin | Controls cell shape and motility |
| 53BP1 | DNA repair protein de-ADP-ribosylated by NUDT16 | Determines DNA repair pathway choice |
| C3 toxin | Bacterial enzyme that ADP-ribosylates and de-ADP-ribosylates Rho | Tool for studying Rho signaling |
| Iota-toxin | Clostridium perfringens toxin that de-ADP-ribosylates actin | Model for actin regulation |
| C2 toxin | Clostridium botulinum toxin that de-ADP-ribosylates actin | Investigates cytoskeletal dynamics |
| Endogenous acceptors | Proteins in human neutrophils subject to DNA-regulated de-ADP-ribosylation | Immune cell signaling |
How Is protein de-ADP-ribosylation Regulated?
Protein de-ADP-ribosylation is regulated at multiple levels. Enzyme activity can be modulated by cofactors such as EDTA, guanine nucleotides, and pH, as demonstrated for Rho de-ADP-ribosylation by Clostridium botulinum C3. DNA regulates arginine-specific mono-ADP-ribosylation and de-ADP-ribosylation of endogenous proteins in human neutrophils. Additionally, substrate availability and post-translational modifications of hydrolases influence the efficiency and specificity of the reaction. For example, NUDT16 activity toward 53BP1 is critical for DNA repair and is likely coordinated with the DNA damage response.
protein de-ADP-ribosylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NUDT16 | Cancer, DNA repair deficiency | Knockout cell lines to assess 53BP1 stability and DNA damage sensitivity |
| TARG1 | Neurodegeneration | Knock-in of patient mutations in neuronal cells |
| MACROD2 | Cancer, neurodevelopmental disorders | Overexpression and knockout models to study ADP-ribose removal |
| Rho | Bacterial toxin pathogenesis | Point mutations to block de-ADP-ribosylation by C3 toxin |
| Actin | Cytoskeletal disorders | Knock-in of actin variants to study iota-toxin effects |
Cancer
Dysregulation of protein de-ADP-ribosylation contributes to cancer by affecting DNA repair and genomic stability. NUDT16 reverses 53BP1 ADP-ribosylation, and its loss leads to impaired DNA repair and increased sensitivity to DNA-damaging agents, highlighting its tumor-suppressive role. Similarly, mutations in macrodomain hydrolases such as MACROD2 are associated with cancer progression.
Neurodegeneration
Defects in de-ADP-ribosylation are linked to neurodegenerative diseases. Mutations in TARG1 cause a severe neurodegenerative disorder characterized by progressive brain atrophy, due to impaired removal of ADP-ribose from proteins and accumulation of DNA damage. This underscores the importance of de-ADP-ribosylation in neuronal survival.
Infectious diseases
Bacterial toxins exploit de-ADP-ribosylation to manipulate host cells. Clostridium botulinum C3 toxin and Clostridium perfringens iota-toxin de-ADP-ribosylate Rho and actin, respectively, disrupting cytoskeletal dynamics and contributing to pathogenesis. Understanding these mechanisms can inform therapeutic strategies against bacterial infections.
From protein de-ADP-ribosylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NUDT16 regulate 53BP1 stability? | NUDT16 knockout cell lines |
| How does TARG1 mutation affect neuronal survival? | Knock-in of TARG1 mutations in iPSC-derived neurons |
| What is the role of MACROD2 in DNA repair? | MACROD2 overexpression and knockout in cancer cells |
| Can C3 toxin de-ADP-ribosylate Rho in vivo? | Point-mutated Rho knock-in mice |
| How does actin de-ADP-ribosylation affect cytoskeleton? | Actin tagged knock-in cells |
| What is the impact of NADAR on DNA ADP-ribosylation? | NADAR knockout bacterial strains |
How to Study the protein de-ADP-ribosylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mono-ADP-ribosylhydrolase assay | Enzymatic removal of ADP-ribose | Characterizing hydrolase activity |
| Mass spectrometry | ADP-ribosylated protein identification | Global profiling of de-ADP-ribosylation targets |
| CRISPR knockout screen | Gene requirement for de-ADP-ribosylation | Identifying novel regulators |
| Western blot with ADP-ribose antibodies | Levels of ADP-ribosylated proteins | Validating de-ADP-ribosylation in cells |
| Fluorescence microscopy | Subcellular localization of de-ADP-ribosylation | Live-cell imaging |
| NAD+ labeling | ADP-ribose turnover | Tracking modification dynamics |
| qPCR | Expression of hydrolase genes | Gene expression analysis |
| Co-immunoprecipitation | Protein-protein interactions | Identifying substrate-hydrolase complexes |
Mono-ADP-ribosylhydrolase assays
These assays measure the enzymatic removal of ADP-ribose from substrate proteins using radioactive or fluorescently labeled ADP-ribose. They are essential for characterizing hydrolase activity and specificity.
Mass spectrometry-based proteomics
Proteomic approaches identify and quantify ADP-ribosylated proteins and their de-ADP-ribosylated counterparts, providing global insights into the modification landscape.
CRISPR-Cas9 knockout screens
Genome-wide knockout screens can identify genes required for de-ADP-ribosylation and its downstream effects, such as DNA repair and cell survival.
Imaging and live-cell assays
Fluorescently tagged ADP-ribose-binding domains or hydrolases allow real-time visualization of de-ADP-ribosylation dynamics in living cells.
How CRISPR Can Be Used to Study GO:0051725 protein de-ADP-ribosylation
Knockout
CRISPR knockout of de-ADP-ribosylation genes such as NUDT16 or MACROD2 enables researchers to assess loss-of-function phenotypes, including DNA repair defects and altered ADP-ribose levels.
Point Mutation
Introducing point mutations in catalytic residues of hydrolases (e.g., NUDT16 or TARG1) via CRISPR allows precise dissection of enzymatic activity versus scaffolding functions.
Knock-in
Knock-in of disease-associated mutations, such as those in TARG1 linked to neurodegeneration, provides models to study the impact of impaired de-ADP-ribosylation on cellular physiology.
Overexpression
CRISPR-mediated overexpression of hydrolases like PARG or MACROD1 can be used to enhance de-ADP-ribosylation and study its effects on DNA repair and cell survival.
How EDITGENE Supports protein de-ADP-ribosylation Research
Researchers studying protein de-ADP-ribosylation-related genes often need to determine whether a candidate gene is causally involved in the process, and CRISPR-based models provide a robust approach to dissect gene function and validate therapeutic targets.
Contact EDITGENE today to design your custom CRISPR model for protein de-ADP-ribosylation research.
Frequently Asked Questions About protein de-ADP-ribosylation
What is protein de-ADP-ribosylation?
Protein de-ADP-ribosylation (GO:0051725) is the biological process that removes one or more ADP-ribose residues from a protein, reversing ADP-ribosylation.
What genes are involved in protein de-ADP-ribosylation?
Key genes include NUDT16, MACROD1, MACROD2, TARG1, ARH1, ARH2, ARH3, and PARG, which encode ADP-ribosylhydrolases.
How does protein de-ADP-ribosylation work?
Hydrolases recognize ADP-ribosylated proteins, hydrolyze the ADP-ribose-protein bond, and release ADP-ribose, restoring protein function.
Why is protein de-ADP-ribosylation important?
It regulates DNA repair, cytoskeletal dynamics, and immune responses, and its dysregulation is linked to cancer and neurodegeneration.
What diseases are associated with defective protein de-ADP-ribosylation?
Cancer, neurodegeneration, and infectious diseases are associated with defects in this process.
What methods are used to study protein de-ADP-ribosylation?
Common methods include mono-ADP-ribosylhydrolase assays, mass spectrometry, CRISPR screens, and imaging.
Can CRISPR be used to study protein de-ADP-ribosylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect gene function in this process.
What is the role of NUDT16 in de-ADP-ribosylation?
NUDT16 is a Nudix hydrolase that reverses 53BP1 ADP-ribosylation, regulating DNA repair and genome stability.
How is protein de-ADP-ribosylation regulated?
It is regulated by cofactors such as EDTA, guanine nucleotides, pH, and DNA, as well as by substrate availability.
What are the synonyms for protein de-ADP-ribosylation?
Synonyms include poly(ADP-ribose) removal from protein, protein poly(ADP-ribose) catabolic process, and removal of ADP-ribose from protein.
Conclusion
Protein de-ADP-ribosylation (GO:0051725) is a fundamental biological process that reverses ADP-ribosylation, thereby controlling protein function in DNA repair, cytoskeletal dynamics, and immune signaling. The growing understanding of hydrolases such as NUDT16, MACROD2, and TARG1 has revealed their critical roles in health and disease, including cancer and neurodegeneration. Continued research using CRISPR models and advanced assays will further illuminate the therapeutic potential of targeting this process.
References
- 1. Abplanalp J et al.. 2018. Mono-ADP-Ribosylhydrolase Assays.. Methods Mol Biol 1813:205-213 PMID: 30097869
- 2. Zhang F et al.. 2020. Nudix Hydrolase NUDT16 Regulates 53BP1 Protein by Reversing 53BP1 ADP-Ribosylation.. Cancer Res 80(5):999-1010 PMID: 31911551
- 3. Cihlova B et al.. 2024. Specificity of DNA ADP-Ribosylation Reversal by NADARs.. Toxins (Basel) 16(5) PMID: 38787060
- 4. Koch-Nolte F et al.. 2008. Mammalian ADP-ribosyltransferases and ADP-ribosylhydrolases.. Front Biosci 13:6716-29 PMID: 18508690
- 5. Habermann B et al.. 1991. ADP-ribosylation and de-ADP-ribosylation of the rho protein by Clostridium botulinum exoenzyme C3. Regulation by EDTA, guanine nucleotides and pH.. Biochim Biophys Acta 1077(3):253-8 PMID: 1827595
- 6. Schuller M et al.. 2023. Molecular basis for the reversible ADP-ribosylation of guanosine bases.. Mol Cell 83(13):2303-2315.e6 PMID: 37390817
- 7. Just I et al.. 1990. De-ADP-ribosylation actin by Clostridium perfringens iota-toxin and Clostridium botulinum C2 toxin.. Eur J Biochem 192(3):723-7 PMID: 2145159
- 8. Obara S et al.. 1989. DNA-regulated arginine-specific mono(ADP-ribosyl)ation and de-ADP-ribosylation of endogenous acceptor proteins in human neutrophils.. Biochem Biophys Res Commun 163(1):452-7 PMID: 2505768
